Our Pipeline
Boosting cell therapies against solid tumors
We are continually working to develop and efficiently move our products through regulatory requirements and clinical testing. Our platform’s modular nature and application flexibility has allowed us to develop multiple commercialization avenues, but we are focusing on the use of T-cells for our initial pipeline.
We currently have three ongoing programs. The first program uses the CTSR module in the context of a B7H3 CAR T-cell to enhance CAR activity and increases their survival in advanced solid tumors. This program is soon entering IND enabling studies. The other two programs are in the discovery phase and deal with CTSR applications in the context of engineered T-cells.
Benefits of including the CTSR technology in an in-vivo Pancreatic Tumor System
B7H3 CAR T cells perform poorly in this pancreatic cell xenograft system but the inclusion of the CTSR module dramatically improves survival.